Mitotic Count and Estimation of the Risk of GIST Recurrence in Patients Treated with Preoperative Imatinib
Mitotic Count and Estimation of the Risk of GIST Recurrence in Patients Treated with Preoperative Imatinib
Author Info
Heikki Joensuu Mikael Eriksson
Corresponding Author
Mikael ErikssonDepartment of Oncology, Skane University Hospital and Lund University, Lund, Sweden
A B S T R A C T
Preoperative imatinib is used frequently in the treatment of large localized GISTs to shrink the tumor prior to surgery. This approach may lead to challenges in the estimation of the risk of recurrence and the need of adjuvant imatinib, because the diagnosis is usually made from a needle biopsy with scant tissue for the assessment of GIST mitotic activity, a key prognostic factor. We propose a mitosis count multiplication method as a proxy for estimating the tumor mitotic count in select cases.
Article Info
Article Type
Short CommunicationPublication history
Received: Sun 13, Oct 2019Accepted: Fri 08, Nov 2019
Published: Mon 30, Dec 2019
Copyright
© 2023 Mikael Eriksson. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Hosting by Science Repository.DOI: 10.31487/j.COR.2019.5.15